Trial reportJournal of the American Academy of Child and Adolescent Psychiatry2010
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Trial report in Journal of the American Academy of Child and Adolescent Psychiatry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 36 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Schizophrenia and Related Disorders in Children and Adolescents
Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)
Who cites it
36 citing papers in PubMed, 7 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Drugs used in psychiatry causing an increase in body weight in children-a review.International journal of obesity (2005) · 2025Pooled it
- Immune and oxidative stress biomarkers in pediatric psychosis and psychosis-risk: Meta-analyses and systematic review.Brain, behavior, and immunity · 2024Pooled it
- Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis.The international journal of neuropsychopharmacology · 2023Pooled it
- Sex Differences in Serum Prolactin Levels in Children and Adolescents on Antipsychotics: A Systematic Review and Meta-Analysis.Current neuropharmacology · 2023Pooled it
- Pharmacological interventions for prevention of weight gain in people with schizophrenia.The Cochrane database of systematic reviews · 2022Pooled it
- Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.PharmacoEconomics · 2015Pooled it
- Antipsychotics in children and adolescents with schizophrenia: a systematic review and meta-analysis.Indian journal of pharmacologyPooled it
- Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.Journal of child and adolescent psychopharmacology · 2021Trial
- Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.Journal of child and adolescent psychopharmacology · 2015Trial
- Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study.Journal of child and adolescent psychopharmacology · 2013Trial
- Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study.Journal of child and adolescent psychopharmacology · 2013Trial
- Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.Journal of the American Academy of Child and Adolescent Psychiatry · 2012Trial
- Review
- Neurological Adverse Effects of Antipsychotic Medication in Children and Young People.Paediatric drugs · 2026Review
- Practitioner Review: Psychosis in children and adolescents.Journal of child psychology and psychiatry, and allied disciplines · 2023Review
- Long-term use of antidepressants, mood stabilizers, and antipsychotics in pediatric patients with a focus on appropriate deprescribing.The mental health clinician · 2021Article
- Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone.Journal of psychopharmacology (Oxford, England) · 2021Article
- Dietary Consumption Among Youth with Antipsychotic-Induced Weight Gain and Changes Following Healthy Lifestyle Education.Journal of child and adolescent psychopharmacology · 2021Article
- Article
- The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.Frontiers in psychiatry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 1 country.
Funding
Abstract
objectiveTo examine the long-term safety and efficacy of three antipsychotics in early-onset schizophrenia spectrum disorders.
methodPatients (8 to 19 years old) who had improved during an 8-week, randomized, double-blind acute trial of olanzapine, risperidone, or molindone (plus benztropine) were eligible to continue on the same medication for up to 44 additional weeks under double-blind conditions. Adjunctive medications were allowed according to defined algorithms. Standardized symptom, safety, and functional assessments were conducted every 4 weeks.
resultsOf the 116 youths randomized in the acute trial, 54 entered maintenance treatment (molindone, n = 20; olanzapine, n = 13; risperidone, n = 21). Fourteen (26%) completed 44 weeks of treatment. Adverse effects (n = 15), inadequate efficacy (n = 14), or study nonadherence (n = 8) were the most common reasons for discontinuation. The three treatment arms did not significantly differ in symptom decrease or time to discontinuation. Akathisia was more common with molindone and elevated prolactin concentrations more common with risperidone. Although weight gain and metabolic adverse events had occurred more often with olanzapine and risperidone during the acute trial, no significant between-drug differences emerged in most of these parameters during maintenance treatment.
conclusionsOnly 12% of youths with early-onset schizophrenia spectrum disorders continued on their originally randomized treatment at 52 weeks. No agent demonstrated superior efficacy, and all were associated with side effects, including weight gain. Improved treatments are needed for early-onset schizophrenia spectrum disorders. Clinical trial registry information-Treatment of Schizophrenia and Related Disorders in Children and Adolescents; URL: http://www.clinicaltrials.gov, unique identifier: NCT00053703.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.